Pre-Clinical
Development
Accelerate your molecule from discovery to first‑in‑human. Low‑volume, high‑throughput pre‑clinical formulation screening designed to optimise solubility, bioavailability, and early‑stage success.
Our pre‑clinical formulation screening platform enables rapid, low‑cost identification of the most promising formulation approach for early drug development. Using minimal API, SGS provides data‑rich screening to optimise solubility, permeability and overall developability—supporting progression into TOX and ADME studies with confidence.
Rapid, decision-enabling data
Key Benefits
High‑throughput screening delivers fast turnaround (≈6 weeks), allowing you to advance programs without delay.
Minimal API consumption
Workflows are designed for situations with very limited API availability, a common constraint in early development.
Enhanced solubility and absorption
Tailored solvent/excipient selection and thermodynamic/kinetic solubility testing improve a molecule’s bioavailability and downstream manufacturability.
Supports TOX & ADMA readiness
Prototype batches and formulation insights help you enter toxicology studies with robust, data‑supported materials.
- Solid‑state and drug‑substance characterization (DSC/TGA, XRF, XRPD, particle size analysis, nano‑milling)
- Small‑scale solubility screening (viscometry, turbidity, pH, density, gravimetric and microscopy analysis)
- Prototype infusion & precipitation assessment (DLS, turbidity, mechanical/visual assessments)
- Excipient & solvent selection to maximise solubility and stability
- Batch production to support early toxicology and ADME requirements
Our capabilties include:
This early‑stage support is designed to help you derisk complex molecules, understand key developability constraints, and identify viable formulation strategies long before scale‑up begins.
